CSIMarket
 

Healthcare Sector

In Vitro & In Vivo Diagnostic Substances Industry Growth  


Growth Rates by Company within In Vitro & In Vivo Diagnostic Substances Industry




Revenue Growth Net Income Growth
Company Quarter Y / Y Sequential Y / Y Sequential
Arca Biopharma Inc 3Q 2023 - - - -
Achieve Life Sciences Inc 3Q 2023 - - - -
Aspira Women s Health Inc 4Q 2023 down-1.07 % down -3.92 % - -
Biomerica Inc 2Q 2023 down-79.1 % down -0.29 % - -
Burzynski Research Institute Inc 4Q 2023 - - - -
Cardio Diagnostics Holdings Inc 1Q 2024 down-99.72 % down -99.7 % - -
Celldex Therapeutics inc 1Q 2024 down-83.87 % down -96.22 % - -
Heska Corporation 1Q 2023 down-3.73 % down -5.96 % - -
Immucell Corp 3Q 2023 up 9.82 % up 73.03 % - -
Idexx Laboratories Inc 1Q 2024 up 7.1 % up 6.98 % up 10.06 % up 21.11 %
Lucira Health Inc 3Q 2022 up 157.53 % up 31.53 % - -
Lantheus Holdings Inc 1Q 2024 up 22.96 % up 4.44 % - up 26.78 %
Myriad Genetics Inc 1Q 2024 up 11.59 % up 2.85 % - -
Mymd Pharmaceuticals Inc 1Q 2024 - - - -
Navidea Biopharmaceuticals Inc 3Q 2023 - - - -
Neogen Corporation 3Q 2023 up 72.85 % down -5.2 % down -71.15 % down -73.03 %
Intellia Therapeutics Inc 3Q 2023 down-9.6 % down -11.78 % - -
Nymox Pharmaceutical Corporation 4Q 2022 - - - -
Ortho Clinical Diagnostics Holdings Plc 1Q 2022 down-1.32 % - - down -66.67 %
Oncocyte Corporation 1Q 2024 down-96.31 % down -58.97 % - -
Quidelortho Corp 1Q 2024 down-17.95 % down -4.44 % - -
Quotient Limited 1Q 2022 up 21.55 % up 12.36 % - -
Alpha Teknova Inc 3Q 2023 down-30.12 % down -32.48 % - -
Trinity Biotech Plc 4Q 2023 down-24 % down -24 % - -
Meridian Bioscience Inc 1Q 2022 up 30.45 % up 25.91 % up 9.31 % up 87.43 %
Volitionrx Limited 1Q 2024 up 14.5 % down -29.69 % - -
Revenue
In Vitro & In Vivo Diagnostic Substances Industry

recorded in the 1. Quarter 2024 above average Revenue deterioration of -98.79 % year on year, Total Ranking #16 and ranking within sector #1.

Sequentially Revenues for In Vitro & In Vivo Diagnostic Substances Industry fell by -91.88 %.

More on In Vitro & In Vivo Diagnostic Substances Industry Revenue Growth




Income
In Vitro & In Vivo Diagnostic Substances Industry
in the 1. Quarter 2024 Net loss contracted year on year.

Sequentially, In Vitro & In Vivo Diagnostic Substances Industry Net loss narrowed from previous quarter.

More on In Vitro & In Vivo Diagnostic Substances Industry Income Growth










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com